1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)
1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)
批准号:
10219895
负责人:
Ira M Cheifetz
金额:
$174.22万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-15 至 2024-07-31
关键词:
AdultAdult Respiratory Distress SyndromeBackCannulationsCaringChildChild CareChildhoodClinicalClinical TrialsConsensusCritical CareCritical IllnessCritically ill childrenDataEligibility DeterminationExtracorporeal Membrane OxygenationFrequenciesFutilityGravitationGrowth and Development functionGuidelinesHigh-Frequency VentilationHomeostasisHospital MortalityHospitalsHourHypercapniaHypoxiaImmune responseInferiorIntentionInternationalInterventionIntratracheal IntubationLength of StayLifeLinkLungMechanical ventilationMissionMonitorMultiple Organ FailureNational Heart, Lung, and Blood InstituteOrgan failureOxygenPatient-Focused OutcomesPatientsPediatric Acute Lung InjuryPediatric Acute Respiratory Distress SyndromePediatric Intensive Care UnitsPerfusionProbabilityProne PositionProtocols documentationPublicationsRandomizedRandomized Controlled Clinical TrialsResearchSafetySecondary toStrategic PlanningSupinationSupine PositionSurvivorsTidal VolumeUpdateVentilatorVolutraumaage groupatelectraumabaseclinical practiceexperiencefunctional statushealth related quality of lifeimprovedlung injurymeetingspediatric patientspressurepreventprimary outcomerespiratoryresponserisk benefit ratiosecondary outcomesurfactantsymposiumventilation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Although acute respiratory distress syndrome is a life-threatening and frequent problem experienced by
thousands of children each year, little evidence supports best ventilation practices during their critical illness.
For over 25 years, pediatric critical care clinicians have debated the risk-benefit ratio of supine versus prone
positioning and conventional mechanical ventilation (CMV) versus high-frequency oscillatory ventilation
(HFOV) in the management of these young patients. Without pediatric-specific data, the debate of how best to
care for children with severe Pediatric Acute Respiratory Distress Syndrome (PARDS) will continue and
prevent progress in the field of pediatric critical care.
We propose PROSpect (PRone and OScillation PEdiatric Clinical Trial), a two-by-two factorial, response-
adaptive, randomized controlled clinical trial of supine/prone positioning and CMV/HFOV. Forty-five pediatric
intensive care units (PICUs), 30 U.S. and 15 international (2/3:1/3 split), with at least 5 years of experience
with prone positioning and HFOV in the care of pediatric patients with severe PARDS, that can provide back-
up extracorporeal membrane oxygenation (ECMO) support will participate. Eligible consecutive subjects with
severe PARDS will be randomized within 48 hours of meeting eligibility criteria and within 4 days of
endotracheal intubation to one of four groups: supine/CMV, prone/CMV, supine/HFOV, prone/HFOV. Subjects
who fail their assigned positional and/or ventilation therapy for either persistent hypoxia or hypercapnia may
receive the reciprocal therapy while being considered for ECMO cannulation. Our primary outcome is
ventilator-free days (VFD), where non-survivors receive zero VFDs. We hypothesize that children with severe
PARDS treated with either prone positioning or HFOV will demonstrate ≥2 more VFDs. Our secondary
outcome is nonpulmonary organ failure-free days. We will also explore the interaction effects of prone
positioning with HFOV on VFDs and also investigate the impact of these interventions on 90-day in-hospital
mortality and, among survivors, the duration of mechanical ventilation, PICU and hospital length of stay, and
the trajectory of post-PICU functional status and health-related quality of life (HRQL). Up to 1000 subjects with
severe PARDS will be randomized by age group and direct/indirect lung injury. Adaptive randomization will
begin after 400 subjects provide complete data on VFDs. Any group demonstrating inferiority at a pre-planned
adaptive randomization update analysis will be eliminated to increase allocation to the superior group(s). Data
will be analyzed per intention-to-treat and per-protocol received.
This clinical trial will provide the definitive evidence necessary for the field to consider a major change
in clinical practice in the care of critically ill children with severe PARDS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)
-
批准号:10480739
-
项目类别:
-
资助金额:$169.25万
-
财政年份:2018
-
负责人:Ira M Cheifetz
-
依托单位:
1/2 PROSpect: Prone and Oscillation Pediatric Clinical Trial (CCC)
-
批准号:10677528
-
项目类别:
-
资助金额:$91.72万
-
财政年份:2018
-
负责人:Ira M Cheifetz
-
依托单位:
PREVALENCE OF POSITIVE CELIAC SEROLOGY IN PATIENTS WITH CROHN'S DISEASE
-
批准号:7718936
-
项目类别:
-
资助金额:$0.08万
-
财政年份:2008
-
负责人:Ira M Cheifetz
-
依托单位:
Center for Molecular & Cellular Studies of Ped Disease
-
批准号:8495607
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2003
-
负责人:Ira M Cheifetz
-
依托单位:
海外基金